Liposomal Anthracyclin in the Treatment of Elderly ALL

• Status: Completed
• Trial end date: 2006-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Phase II multicentric study comparing VAD regimen with continuous infusion over 96 hours of doxorubicin, vincristine and dexamethasone to a 90 minutes infusion of equivalent doses of Dox li-PEG, bolus infusion of vincristine and dexamethasone

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: French Innovative Leukemia Organisation
• Treatments: Doxorubicin; Liposomal doxorubicin

Criteria

Inclusion Criteria:

• 55 years of age and older

• ECOG performance/=3

• VIH negative

• Absence of previous ALL treatment

• Informed consent signed

• SGPT and Bilirubin < 4x upper limit of normal

• Normal creatinine for age

• cardiac state compatible with anthacyclin

Exclusion Criteria:

• ALL with Philadelphia Chromosome

• ALL3

• CML blasts crisis

• Cardiac insufficiency and/ or left ventricular ejection fraction < 50%

• Evolutive infection

• Presence of other evolutifs cancer or ongoing treatment

• mental status incompatible with inform consent